What is NexEos Bio?
NexEos Bio is a biotechnology firm focused on pioneering technologies for the identification and treatment of eosinophil and cationic protein-mediated inflammation. The company's dual-pronged approach includes its lead therapeutic candidate, NTX-1024, a topical solution designed for eosinophil-driven ocular diseases, and its diagnostic program, NDX-3324, a non-invasive imaging agent for Eosinophilic Esophagitis. NexEos Bio's commitment lies in enhancing the quality of life for individuals affected by eosinophil-related conditions, driven by a mission of urgency and innovation to deliver superior management strategies for these debilitating ailments.
How much funding has NexEos Bio raised?
NexEos Bio has raised a total of $3M across 1 funding round:
Private Equity
$3M
Private Equity (2026): $3M, investors not publicly disclosed
What's next for NexEos Bio?
The recent major strategic investment of $3M positions NexEos Bio for significant advancement, likely indicating a transition into a scaling or late-stage development phase. This capital will be instrumental in accelerating the clinical development of NTX-1024 and expanding the reach of NDX-3324. The company is expected to leverage this backing to further its research and development efforts, potentially forging new partnerships and expanding its market presence in the specialized field of eosinophil-related disease therapeutics and diagnostics. Strategic deployment of these funds will be critical for achieving key regulatory milestones and bringing their innovative treatments to patients.
See full NexEos Bio company page
